**Composition**
For one immunizing dose:
Powder:
- Freeze-dried rabies vaccine (WISTAR strain RABIES PM/38-1503-3M) produced on VERO cell line, inactivated and purified
  1 immunizing dose*
- Maltose: up to 1 immunizing dose
- Human plasma albumin: up to 1 immunizing dose

*Diluent:
- 4% sodium chloride solution: 0.5 ml
  Such that the protective power is greater than or equal to 2.5 IU before and after heating for 1 month at 37ºC.

**Pharmaceutical Dosage Form**
Powder and diluent for suspension H injection.

**Indications**
This medicinal product is a vaccine.

Pre-exposure
This vaccine is recommended for the prevention of rabies in subjects at a high risk of exposure.

All subjects at a permanent risk, such as diagnostic, research and production laboratory staff working on rabies virus, should be vaccinated. A serological test is recommended every 6 months. A booster injection should be administered when the antibody titre is below the level considered to guarantee protection: 0.5 IU/ml.

The following categories should be vaccinated given the frequency of exposure to the risk:
- veterinarians (and assistants), game-keepers, hunters, forest rangers, slaughterhouse personnel, cavers, taxidermists,
- subject exposed to enzootic areas: children, adults and travellers visiting these areas.

Post-exposure
After confirmed or suspected exposure, vaccination must be started immediately at the slightest risk of contamination with rabies. It must be performed in a rabies treatment centre.

The treatment is adapted to the type of wound and the status of the animal.

**Contraindications**
This medicinal product MUST NOT BE USED in the following cases:

Pre-exposure
- severe febrile infection, acute disease, progressive chronic disease (it is preferable to postpone vaccination),
- known hypersensitivity to any of the ingredients of the vaccine

Post-exposure
Due to the fatal progression of declared rabies infection, there are no contraindications to curative vaccination.

Pregnancy: see Pregnancy and Lactation section. If there is any doubt, it is essential to consult your doctor or your pharmacist.

**Side Effects**
As for any active product, this medicinal product may induce undesirable effects to a varying degree in certain subjects:
- Minor local reactions: pain, erythema, oedema, pruritus and induration at the injection point.
- Systemic reactions: moderate fever, shivering, faintness, asthenia, headaches, dizziness, arthralgia, myalgia, gastro-intestinal disorders (nausea, abdominal pains).
- Exceptionally, anaphylactoid reactions, urticaria, rash.

Report to the doctor or to the pharmacist any unwanted and disturbing effects which might not be mentioned in this leaflet.

**Warnings**
Use with caution on subjects with a known allergy.
to neomycin (present in trace form in the vaccine). Do not inject by the intravascular route: make sure that the needle does not enter a blood vessel. Immunoglobulins and rabies vaccine must not be associated in the same syringe or injected at the same site. A serological test (neutralizing antibody assay using the RFFIT (Rapid Fluorescent Focus Inhibition Test) test) must be conducted on persons subject to continuous exposure (every 6 months) and may be conducted every 2 to 3 years after the booster dose after 1 and 5 years in persons subject to discontinuous exposure according to the assessed exposure risk. For immunodeficient subjects, this test may be conducted 2 to 4 weeks following the vaccination. If the result of the test demonstrates an antibody titre <0.5IU/ml, a booster injection or an additional injection, for immunodeficient subjects, is justified.

This vaccine must never be administered by the intravascular route.

**Precautions**

Inform the doctor in the event of known allergy to neomycin, due to the use of these substances during production.

If there is any doubt, do not hesitate to consult the doctor or the pharmacist.

Keep out of the reach of children.

**Pregnancy and Lactation**

The vaccine has not been the subject of animal teratogenicity studies.

In the absence of sufficient human data, it is recommended to postpone pre-exposure vaccination. For the vaccination of subjects at a high risk of contamination, the benefit/risk ratio must be assessed before administering the injection. In post-exposure vaccination, due to the severity of the disease, pregnancy is not a contraindication. As a general rule, during pregnancy and lactation, it is recommended to always ask the doctor or pharmacist for advice before using a medicinal product.

**Storage**

Do not exceed the expiry date stated on the external packaging.

Keep between +2°C and +8°C (in a refrigerator).

**Drug Interactions**

Corticosteroids and immunosuppressor treatments may interfere with antibody production and cause the vaccination to fail. Therefore, it is preferable to conduct a neutralizing antibody assay 2 to 4 weeks after the last injection of vaccine. In order to avoid possible interactions between several medicinal products, any other ongoing treatment should be systematically reported to the doctor or to the pharmacist.

**Dosage and Administration**

The vaccination schedule should be adapted according to the circumstances of the vaccination and the subjects rabies immune status.

Preventive or pre-exposure vaccination
- primary vaccination: 3 injections on D0, D7, D28.
- booster injection 1 year later.
- booster injections every 5 years.

The injection scheduled on D28 may be administered on D21.

“Curative” vaccination (prevention of rabies after confirmed or suspected exposure).

**First Aid Treatment**

The treatment of wounds is very important and must be performed promptly after the bite. It is recommended firstly to wash the wound with large quantities of water and soap or detergent and then apply 70, alcohol, tincture of iodine or a 0.1 per cent quaternary ammonium solution (provided that no soap remains as these two products neutralize each other). Curative vaccination must be administered under medical supervision and only in a rabies treatment centre.

**Vaccination of non-immunized subjects**

The dosage is the same for adults and for children: it includes 5 x 0.5 ml injections on D0, D3, D7, D14 and D28.

In the case of category III exposure (see Indications
- Table 2), rabies immunoglobulins must be administered in association with the vaccine. Additional passive immunization on day 0 is required with:

- human rabies immunoglobulin (H RI): 20 IU / kg of body weight
- equine rabies immunoglobulin: 40 IU / kg of body weight

If possible, the vaccine should be injected on the side opposite the immunoglobulin administration sites.

In enzootic areas, the severity of certain exposures due to the severity of the lesions and/or location (proximity of the central nervous system), a late consultation or immunodeficiency of the subject may justify, depending on the case, 2 injections on D0.

**Vaccination of subjects already immunized**

Vaccination administered less than 5 years previously (cell culture rabies vaccine): 2 injections: D0, D3.

Vaccination administered over 5 years previously or incomplete: 5 injections: D0, D3, D7, D14 and D28 with administration of immunoglobulins if required.

In practice, if the last booster dose was administered over 5 years previously or if the vaccination is incomplete, the subject is considered to have an uncertain vaccination status.

**Mode and Route of Administration**

To reconstitute the vaccine, introduce the diluent into the vial of powder and shake thoroughly until the powder is completely suspended. The solution should be homogenous, clear and free of any partic-